210 related articles for article (PubMed ID: 17346156)
1. Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.
Xu J; Peng H; Zhang JT
Curr Med Chem; 2007; 14(6):689-701. PubMed ID: 17346156
[TBL] [Abstract][Full Text] [Related]
2. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Han B; Zhang JT
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
[TBL] [Abstract][Full Text] [Related]
4. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
Peng H; Dong Z; Qi J; Yang Y; Liu Y; Li Z; Xu J; Zhang JT
PLoS One; 2009 May; 4(5):e5676. PubMed ID: 19479068
[TBL] [Abstract][Full Text] [Related]
5. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
6. ABCG2: structure, function and role in drug response.
Polgar O; Robey RW; Bates SE
Expert Opin Drug Metab Toxicol; 2008 Jan; 4(1):1-15. PubMed ID: 18370855
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.
Ejendal KF; Hrycyna CA
Curr Protein Pept Sci; 2002 Oct; 3(5):503-11. PubMed ID: 12369998
[TBL] [Abstract][Full Text] [Related]
8. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
9. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
Ni Z; Bikadi Z; Rosenberg MF; Mao Q
Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902
[TBL] [Abstract][Full Text] [Related]
10. ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2.
Wang DS; Patel A; Sim HM; Zhang YK; Wang YJ; Kathawala RJ; Zhang H; Talele TT; Ambudkar SV; Xu RH; Chen ZS
J Cell Biochem; 2014 Aug; 115(8):1381-91. PubMed ID: 24939447
[TBL] [Abstract][Full Text] [Related]
11. Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.
Peng H; Qi J; Dong Z; Zhang JT
PLoS One; 2010 Dec; 5(12):e15276. PubMed ID: 21151870
[TBL] [Abstract][Full Text] [Related]
12. High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance.
Saito H; Hirano H; Ishikawa T
Mini Rev Med Chem; 2007 Oct; 7(10):1009-18. PubMed ID: 17979803
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
14. Molecular pharmacology of ABCG2 and its role in chemoresistance.
Stacy AE; Jansson PJ; Richardson DR
Mol Pharmacol; 2013 Nov; 84(5):655-69. PubMed ID: 24021215
[TBL] [Abstract][Full Text] [Related]
15. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
Hasanabady MH; Kalalinia F
J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
Chearwae W; Shukla S; Limtrakul P; Ambudkar SV
Mol Cancer Ther; 2006 Aug; 5(8):1995-2006. PubMed ID: 16928820
[TBL] [Abstract][Full Text] [Related]
17. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies.
Westover D; Li F
J Exp Clin Cancer Res; 2015 Dec; 34():159. PubMed ID: 26714461
[TBL] [Abstract][Full Text] [Related]
18. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
Ozvegy-Laczka C; Cserepes J; Elkind NB; Sarkadi B
Drug Resist Updat; 2005; 8(1-2):15-26. PubMed ID: 15939339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
